Population pharmacokinetic modelling of rupatadine solution in 6–11 year olds and optimisation of the experimental design in younger children
نویسندگان
چکیده
AIMS To optimise a pharmacokinetic (PK) study design of rupatadine for 2-5 year olds by using a population PK model developed with data from a study in 6-11 year olds. The design optimisation was driven by the need to avoid children's discomfort in the study. METHODS PK data from 6-11 year olds with allergic rhinitis available from a previous study were used to construct a population PK model which we used in simulations to assess the dose to administer in a study in 2-5 year olds. In addition, an optimal design approach was used to determine the most appropriate number of sampling groups, sampling days, total samples and sampling times. RESULTS A two-compartmental model with first-order absorption and elimination, with clearance dependent on weight adequately described the PK of rupatadine for 6-11 year olds. The dose selected for a trial in 2-5 year olds was 2.5 mg, as it provided a Cmax below the 3 ng/ml threshold. The optimal study design consisted of four groups of children (10 children each), a maximum sampling window of 2 hours in two clinic visits for drawing three samples on day 14 and one on day 28 coinciding with the final examination of the study. CONCLUSIONS A PK study design was optimised in order to prioritise avoidance of discomfort for enrolled 2-5 year olds by taking only four blood samples from each child and minimising the length of hospital stays.
منابع مشابه
Radiographic Evaluation of the Developmental Stages of Second and Third Molars in 7 to 11-Year-old Children and its Implication in the Treatment of First Molars with Poor Prognosis
Background and aim: First permanent molars with poor prognosis may be candidate for timely extraction and replacement by second permanent molars. The presence of third molars should be considered in this treatment plan. The aim of the present study was to evaluate the critical developmental stages of permanent second molar and the status of third molar bud in an Iranian population. Materials an...
متن کاملPD39 - Application of population pharmacokinetic modeling and simulation in the design of the optimal dose regime of rupatadine in children 2-5 year old children
Methods A popPK model was developed, using data from 6-11 y/o study (STD I) including 11 patients with full PK profile in allergic rhinitis. A second study (STD2) including 2-5 y/o was optimal designed based on the parameters estimated from STD I, assuming: inclusion of < 40 children, < 5 samples per child in the shortest time window. A final popPK model was built for children 2-11 years. Influ...
متن کاملEmergency department resource optimisation for improved performance: a review
Emergency departments (EDs) have been becoming increasingly congested due to the combined impacts of growing demand, access block and increased clinical capability of the EDs. This congestion has known to have adverse impacts on the performance of the healthcare services. Attempts to overcome with this challenge have focussed largely on the demand management and the application of system wide p...
متن کاملExamining the Factors Related to Mortality Aamongst One Year Old and Younger Children in Yazd City During 2011 to 2013 Period
Background: Provision, maintaining and improving health status of one year old and younger children as a vulnerable group has been considered as an important issue pertaining to healthcare/medical services. Index of mortality of under one year old children is among most important healthcare indices and is known as the most important index of healthcare status of any society as well as the quali...
متن کاملO10 - Rupatadine is effective and safe in the treatment of Chronic Spontaneous Urticaria (CSU) in pediatric patients (2-11 years old)
Background Rupatadine is an anti-H1/PAF antagonist that has proven to be effective and safe in adults/adolescents for Allergic Rhinitis (AR) and Urticaria. In addition, Rupatadine has been recently licensed for the symptomatic treatment of AR in children aged 6-11 years. The aim of this study was to assess the efficacy and safety of Rupatadine oral solution in children with Chronic Spontaneous ...
متن کامل